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Abstract
Soil bacteria may contain antibiotic resistance genes responsible for different mechanisms that permit them to overcome the natural
antibiotics present in the environment. This gene pool has been recently named the ‘resistome’, and its components can be mobilized
into the microbial community affecting humans because of the participation of genetic platforms that efﬁciently facilitate the mobilization
and maintenance of these resistance genes. Evidence for this transference has been suggested or demonstrated with newly identiﬁed
widespread genes in multidrug-resistant bacteria. These resistance genes include those responsible for ribosomal methylases affecting
aminoglycosides (armA, rtmB), methyltransferases affecting linezolid (cfr) or plasmid-mediated efﬂux pumps conferring low-level ﬂuoro-
quinolone resistance (qepA), all of which are associated with antibiotic-producing bacteria. In addition, resistance genes whose ancestors
have been identiﬁed in environmental isolates that are not recognized as antibiotic producers have also been recently detected. These
include the qnr and the blaCTX genes compromising the activity of ﬂuoroquinolones and extended-spectrum cephalosporins, respectively.
The application of metagenomic tools and phylogenetic analysis will facilitate future identiﬁcation of other new resistance genes and
their corresponding ancestors in environmental bacteria, and will enable further exploration of the concept of the resistome as being a
unique reservoir of antibiotic resistance genes and genetic elements participating in resistance gene transfer.
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During the last decade, an increase in rates of antimicrobial
resistance has been recognized worldwide, and an increased
frequency of multidrug-resistant (MDR) isolates in the clinical
setting has been demonstrated. Moreover, the term extreme
drug resistance has been applied to those isolates for which
there are no available therapeutic options [1]. The acceler-
ated emergence and description of new mechanisms of resis-
tance and the recognition of efﬁcient surrounding genes and
genetic platforms facilitating capture, transfer and expression
of resistance determinants are also subjects of intense
investigation. These studies also include the origin of the
resistance determinants and the corresponding surrounding
genetic platforms.
Pathways for resistance
To become resistant to antimicrobial agents, bacterial com-
munities use different strategies, including both natural and
engineering responses [2]. Natural responses include: (i) the
use of pre-existing bacterial machinery, i.e. the use of resis-
tance genes from other bacteria; and (ii) gene variation
(mutation) in pre-existing genes (pro-active response) or in
acquired genes (post-active response). Some of these strat-
egies require engineering processes involving different
genetic platforms that are used for mobilization, acquisition
and assembly of foreign resistance genes. In addition to
these mechanisms, bacterial growth in bioﬁlms might also
enhance resistance to antimicrobial agents (physiological
response).
Resistance response using pre-existing machinery from natu-
ral antibiotic-producing bacteria is widely recognized in resis-
tance pathogens. Table 1 illustrates different examples involving
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classic and new antibiotic resistance mechanisms. Most of these
have been associated with Streptomyces spp. recovered from
soil, and involve inactivating resistance mechanisms, efﬂux pro-
cesses or antibiotic target modiﬁcations [2]. In the last few
years, it has been demonstrated that antibiotic resistance mech-
anisms can also originate in environmental bacteria that appar-
ently do not produce antibiotics. Most mechanisms are cryptic
resistance determinants in the natural bacteria that are efﬁ-
ciently expressed in the new host. This fact is exempliﬁed by
the CTX-M extended-spectrum b-lactamases (ESBLs), which
constitute one of the most successfully spread resistance mech-
anisms affecting expanded-spectrum cephalosporins, or by the
Qnr-related topoisomerase protective proteins, which com-
promise ﬂuoroquinolone activity [3,4].
The blaCTX-M genes have been associated with Kluyvera
spp., whereas the qnr genes have been associated with
Shewanella algae. Both comprise environmental isolates that
have not been recognized as antibiotic producers, but carry
a blaCTX-M gene and a qnrA resistance gene, respectively. In
addition, these organisms do not show intrinsic resistance to
either expanded-spectrum cephalosporins or ﬂuoroquinol-
ones. On the other hand, isolates in the clinical setting har-
bouring these genes are of clinical signiﬁcance and are rising
to prominence within the MDR isolates [3,5].
Environmental antibiotic resistome and
antibiotic extended resistome
In recent years, metagenomic tools have identiﬁed resistance
genes in isolates recovered from the environment [6–8].
These genes form part of pre-existing machineries in bacterial
isolates capable of producing substances with antimicrobial
activity or, as recently recognized, as natural intermicrobial sig-
nalling molecules [9]. The term ‘antibiotic resistome’ was pro-
posed for the collection of all antibiotic resistance genes in
microorganisms, including those from pathogenic and non-
pathogenic bacteria. This term exploits the concept of a
unique reservoir of antibiotic resistance genes. It includes
resistance genes in antibiotic producers and precursor genes
that, under appropriate selective pressure, evolve to act as
resistance elements. Most are cryptic resistance genes that are
not naturally expressed in environmental isolates [8].
D’Acosta et al. [6] were the ﬁrst to use the antibiotic resis-
tome concept when constructing a library of up to 480 Strepto-
myces sp. strains recovered from different environmental
sources and subsequently screened against 21 antibiotics.
Within this library, they identiﬁed resistance genes in all strains
and resistance mechanisms affecting not only natural but also
synthetic antimicrobials. Some of these resistance mechanisms,
e.g. inactivation mechanisms affecting daptomycin or telithro-
mycin, two of the newest antimicrobials introduced in thera-
peutics, have not yet been characterized in clinical isolates.
This metagenomic approach has been expanded and is
also now applied to surrounding resistance genes and genetic
elements participating in resistance gene transfer, and is
termed the ‘antibiotic extended resistome’ [7]. This concept
is useful for the exploration of environmental diversity in dif-
ferent ecosystems, including broad settings (e.g. healthcare
settings of nosocomial transmission) or speciﬁc compart-
ments, even in a single patient (e.g. the intestinal compart-
ment), and could be useful for prediction of the future
evolution of antibiotic resistance [10]. The analysis of some
of the recent antibiotic resistance mechanisms described in
the clinical setting reinforces these approaches.
New resistance genes associated with
antibiotic-producing organisms
Aminoglycoside-modifying enzymes, efﬂux-based mechanisms
affecting tetracylines, acetylases modifying chloramphenicol
and RNA methylases conferring resistance to macrolides
(Table 1), among others, have been traditionally considered
Table 1. Natural reservoirs of resistance determinants affecting different antimicrobial agents
Antimicrobial group Mechanisms Related natural protein Natural reservoirs
New resistance genes associated with antibiotic-producing organisms
Aminoglycosides Acetylation Histone acetylases Streptomyces
Phosphorylation Protein kinases
16S ribosomal RNA methylation Methylases Streptomyces, Micromonospora
Tetracyclines Efﬂux (mar) Major facilitator superfamily EF-Tu, EF-G Streptomyces
Chloramphenicol Acetylation Acetylases Streptomyces
Efﬂux (mar) Major facilitator superfamily EF-Tu, EF-G
Macrolides Target mutation 50S ribosomal subunit Streptomyces
New resistance genes associated with non-antibiotic-producing organisms
Fluoroquinolones Topoisomerase protection QnrA-like protein Shewanella algae
QnrS-like protein Vibrio splendidus
b-Lactams Hydrolases PBP (transpeptidases) Kluyvera spp.
PBP, penicillin-binding protein.
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to be resistance mechanisms, the corresponding resistance
determinants for which can be found in natural antibiotic-
producing bacteria. This list has now been enlarged with the




Methylation of the 16S rRNA is the most recently described
resistance mechanism affecting aminoglycosides [11]. It was
ﬁrst identiﬁed in a Citrobacter freundii isolate recovered in
Poland in 2002, and then in Pseudomonas aeruginosa isolates
in Japan and in Klebsiella pneumoniae isolates in France in
2003. Although few recent reports have been published, it
has been also described in other members of the Enterobac-
teriaceae, including Proteus mirabilis, Serratia marcescens, Salmo-
nella spp., Enterobacter aerogenes, Escherichia coli, Shigella
ﬂexneri, Klebsiella oxytoca, and Acinetobacter spp. Most of these
isolates were recovered in clinical settings. In the future, we
will surely encounter an increasing number of publications
depicting the epidemiological situations in which this resis-
tance mechanism has clinical relevance.
The production of the aminoglycoside methylases has
been associated with different gene families, including the
armA, rmtA, rmtB, rmtC and rmtD genes. The amino acid and
nucleotide alignment demonstrates that these genes have
originated from the Actinomicetales, including Streptomyces
and Micromonospora spp. [12]. These genes are linked with
insertion sequences (ISs) that have shown integration, mobili-
zation and expression functions, such as ISCR1 (formerly
ORF 513) or ISEcp1, similar to those encountered with
other emerging resistance genes. All these sequences are
carried in transposable platforms within conjugative plasmids,
allowing potential spread within bacterial populations. More-
over, it is important to note that 16S rRNA methylase genes
have been commonly associated with other resistance genes
that are currently well dispersed in human clinical and veteri-
nary isolates, such as blaBLEE (CTX-M, SHV), plasmid blaAmpC,
blaSPM-1, different aminoglycoside-modifying enzyme genes,
and plasmid-mediated quinolone resistance genes (qepA). All
of these resistance genes allow potential co-selection and
maintenance processes in compartments with high antibiotic
use [11]. Recent studies in isolates of human and animal ori-
gin have shown that some of these genes (e.g. armA) are
associated with a class 1 integron platform structure har-
bouring IS26, whereas other genes (e.g. rmtC) are associated
with complex potential transposons linked to ISEcp1 [13–
15].
Methyltransferases affecting linezolid
Linezolid is an oxazolidinone compound that is active against
Gram-positive isolates, including methicillin-resistant Staphylo-
coccus aureus and vancomycin-resistant enterococcal isolates.
It is a synthetic bacteriostatic compound that inhibits protein
synthesis by binding at the P-site in the ribosomal 50S sub-
unit. Linezolid-resistant isolates have rarely been described.
Resistance is mostly due to mutations in domain V of 23S
RNA, mainly described in clinical methicillin-resistant Staphy-
lococcus aureus and vancomycin-resistant enterococcal iso-
lates and laboratory mutants of Streptococcus pneumoniae
[16]. Deletion in genes encoding the L4 riboprotein has also
been described in S. pneumoniae, and these deletions confer
cross-resistance to macrolides, oxazolidinones and chloram-
phenicol [17]. Moreover, efﬂux pumps affecting linezolid
have been identiﬁed in Mycobacterium tuberculosis [18].
Recently, a methyltransferase affecting the linezolid ribo-
some target and caused by the cfr gene was recognized in
a clinical Staphylococcus aureus isolate recovered in Colom-
bia [19]. The Cfr methyltransferase modiﬁes adenosine at
position 2503 in 23S rRNA in the large ribosomal subunit.
Although linezolid is a synthetic antibiotic, the cfr gene is
thought to be of natural origin and could be responsible
for resistance mechanisms involving protection against natu-
ral antibiotics whose site of action overlaps that of linezo-
lid. The Cfr methyltransferase also affects chloramphenicol,
lincosamides, pleuromutilins and streptogramin A antibiot-
ics. In this Staphylococcus aureus isolate, the cfr gene was
located in the chromosome linked to the ermB gene, which
confers resistance to erythromycin through dimethylation
of A2058 in 23S rRNA. A chromosomal location of the
ermB/cfr operon was previously identiﬁed in transposable
elements within a conjugative plasmid in coagulase-negative
staphylococci of animal origin [20]. This demonstrates dis-
semination of a resistance mechanism of potential environ-
mental origin affecting a synthetic antibiotic, in this case,
linezolid.
Plasmid-mediated quinolone resistance
associated with efﬂux pumps
Traditionally, quinolone resistance mechanisms have been
mainly due to target modiﬁcations and efﬂux pumps. Resis-
tance due to target modiﬁcations is determined by topo-
isomerase mutations (gyrA mutations in Gram-negative
bacteria, and parC in Gram-positive bacteria), whereas resis-
tance due to efﬂux pumps involves different families of
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efﬂux pumps. Both mechanisms are chromosomally medi-
ated and are increasingly recognized in clinical isolates. Dur-
ing the last few years, plasmid-mediated quinolone
resistance mechanisms have been unexpectedly found,
including: (i) Qnr topoisomerase-protective proteins; (ii) the
AAC(6¢)-Ib-cr quinolone-modifying enzyme; and (iii) the
QepA efﬂux pump [4,5,21,22]. The last of these, due to
the qepA gene, was ﬁrst characterized in multiresistant
E. coli isolates recovered in Japan in 2002, which also har-
boured other resistance genes such as blaCTX-M-12, blaTEM-1,
rmtB, and mphA. The qepA gene has also been characterized
in Europe (Belgium) in bacterial collections recovered from
2000 to 2005. These isolates, like those recovered in
Japan, harboured other resistance genes, such blaCTX-M-14,
blaTEM-1, dfrA17, sul1, tet(A), catI, ant39, and rmtB, giving a
multidrug resistance phenotype.
Sequence analysis of the qepA gene and alignment with
other genes have revealed a potential origin in transport sys-
tems (MFS efﬂux pumps) from environmental isolates, such
as Actinomycetales (Nocardia farcinica, Streptomyces globisporus,
and Streptomyces clavuligerus). Recent studies demonstrated
that the qepA gene is linked to transposable elements and
IncF1 plasmids, allowing mobilization among bacterial isolates
[21,22]. These results suggest that there will be future
appearances of this resistance mechanism.
But, from a phenotypic view, wild-type isolates expressing
the qepA gene have higher MICs than those of transconju-
gants, because of the coexistence of other resistance genes
affecting quinolones in the former. Although the QepA
efﬂux pumps confer only a slight incremental increase in
MIC values, their presence might favour the development of
mechanisms expressing even greater resistance [5]. Coexis-
tence of the qepA gene with mechanisms conferring higher
ﬂuoroquinolone resistance might also favour the ﬁxation of
this newly described resistance gene in the bacterial
resistome.
New resistance genes associated with
environmental isolates not recognized as
antibiotic producing isolates
As noted, two new types of resistance genes, the qnr and
the blaCTX determinants affecting ﬂuoroquinolones and
extended-spectrum cephalosporins, respectively, exemplify
this possibility of new means of antimicrobial resistance
appearing among environmental isolates [3,4]. Both of these
recently described genes and mechanisms are expanding rap-
idly within clinical isolates.
Qnr Topoisomerase protective proteins
The Qnr plasmid-mediated resistance mechanism was identi-
ﬁed in 1998 in K. pneumoniae isolates producing b-lactamase
(FOX-5), which affects extended-spectrum cephalosporins,
including metoxi-cephalosporins [23]. The new mechanism
confers protection of topoisomerase from ﬂuoroquinolones
[4]. Like the qepA gene, despite conferring only low-level
resistance to ﬂuoroquinolones, it facilitates the selection of
isolates with high-level resistance, including those with topo-
isomerase mutations [24]. There are different families of
Qnr proteins, QnrA, QnrB and QnrS, that share variable
amino acid similarities. QnrA belongs to the pentapeptide-
repeat family, which is deﬁned by a tandem of ﬁve speciﬁc
amino acid repeats within the protein. Some of these pro-
teins, including McbG, a pentapeptide-repeat protein with
19.6% amino acid identity with QnrA, protects against other
naturally occurring peptides affecting DNA gyrase, such as
microcin B17. Similar proteins have been identiﬁed in Myco-
bacterium smegmatis and M. tuberculosis [4].
The presence of qnr genes has been mainly identiﬁed in
clinical isolates of Enterobacteriaceae with other resistance
mechanisms, such as CTX-M ESBL and other newly
described b-lactamases (VEB-1 and plasmid AmpC-derived
enzymes), aminoglycoside-modifying enzymes, or plasmid-
mediated efﬂux resistance mechanisms [4]. The origin of
qnrA-like genes was determined using a PCR-based strategy
on a series of Gram-negative organisms. The reservoir was
identiﬁed as Shewanella algae, an environmental species from
marine and fresh water. Four variants of qnrA (qnrA2–qnrA5)
were found to be chromosomally mediated in strains of
Shewanella algae [25]. Moreover, the progenitor of qnrS
genes was also found in Vibrio splendidus, and genes similar to
qnr with 40–70% amino acid identity were found in the chro-
mosomes of other water-borne species, including Vibrio vulnif-
icus, Vibrio parahaemolyticus and Photobacterium profundum
[26]. These ﬁndings indicate that gene exchange has
occurred between these environmental organisms and
Enterobacteriaceae, and also support speculation that, under
current intensive ﬂuoroquinolone selective pressure, such
genes have entered circulation on mobile genetic elements
[4].
A recent report has shown an unusual occurrence of the
qnrS2 ﬂuroquinolone resistance determinant in environment-
al Aeromonas spp. recovered from a river in an urban area
in France. The qnrS2 determinant was harboured in a newly
described genetic platform deﬁned as a mobile insertion cas-
sette (‘mic’), resembling a transposon within IncU2 plasmids,
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which are ubiquitous in a wide range of environments. Both
observations increase the possibility of dissemination outside
of natural environmental compartments, and also underscore
that these bacteria may play a role as a reservoir of the qnrS
genes in an aquatic environment, as already shown for other
resistance genes such as tet genes affecting tetracyclines [27].
Despite these ﬁndings, qnr gene mobilization could have
also been performed by the same genetic elements that have
mobilized ribosomal methylase genes affecting aminoglyco-
sides or blaCTXM genes hydrolysing expanded-spectrum ceph-
alosporins (see below). In fact, the search for the
surrounding platform of qnr genes facilitated the identiﬁca-
tion of their genetic linkage with ISCR1, which has been asso-
ciated with all previously mentioned new resistance genes
[3,4,11].
CTX-M ESBLs
The CTX-M ESBLs exemplify one of the most successful
resistance mechanisms that have emerged and spread during
recent years. This family of b-lactamases was ﬁrst described
20 years ago, almost simultaneously in Germany and Argen-
tina. It encompasses ﬁve different groups of enzymes (CTX-
M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25), all of
them displaying potent hydrolytic activity against cefotaxime,
although new variants may also effectively hydrolyse ceftazi-
dime [3].
In recent years, a dramatic increase in these b-lactamases
has been found worldwide in different compartments, partic-
ularly in E. coli in the community setting and also in veteri-
nary isolates. Reasons for this increase include its association
with ISs participating in gene mobilization, such as ISEcp1 or
ISCR1 and phage-related sequences, all of them within conju-
gative plasmids. Although these plasmids are widely dissemi-
nated among clinical isolates and are easily transferred, it is
important that blaCTX-M genes and surrounding genes may
also be linked to class 1 integrons allocated within transpos-
able platforms resembling Tn21 subfamilies. These structures
can integrate resistance gene cassettes and are associated
with resistance to biocides and mercurial compounds that
can participate in co-selection processes. Moreover, it is not
unusual to ﬁnd associations of blaCTX-M genes with those
coding for new emerging resistance mechanisms, e.g. 16S
RNA methylases (armA and rmtB genes), Qnr proteins (qnrA,
qnrB or qnrS), acetylases affecting ﬂuroquinolones (aac(6¢)-Ib-
cr) and systems pumping out ﬂuoroquinolones (qepA); these
genes are found in the same genetic platforms.
From an evolutionary point of view, different Kluyvera spe-
cies have been recognized as progenitors of blaCTX-M genes:
Kluyvera ascorbata for the CTX-M-1 and CTX-M-2 groups,
and Kluyvera georgiana for the CTX-M-8 group. In addition,
phylogenetic analysis showed that blaCTX-M genes have been
mobilized from the chromosome of Kluyvera spp. approxi-
mately ten times more frequently than genes coding for
other class A b-lactamases, which has facilitated the spread
of the blaCTX-M genes. Moreover, the blaCTX-M genes are
descended from a common ancestor that was incorporated
in ancient times into the chromosome of the ancestor of
Kluyvera spp. through horizontal transfer [28]. The expres-
sion of blaCTX-M in Kluyvera is modest, as isolates belonging
to this genus are normally susceptible to expanded-spectrum
cephalosporins. This is not the case in Enterobacteriaceae.
The importance of Kluyvera spp. in nature in recruiting
resistance genes has not been sufﬁciently investigated. It can
also act as a donor of resistance genes to other bacteria. In
fact, the ability of ISEcp1 to mobilize the chromosomal
blaCTX-M gene from one of these Kluyvera progenitors was
shown in an in vitro experiment, and its potential role for
ensemble in conjugative plasmids was also demonstrated
[29].
Conclusions
The ancestors of most of the new resistance genes found in
MDR clinical isolates have been identiﬁed both in antibiotic-
producing bacteria and in environmental isolates not recog-
nized as antibiotic producers. Mobilization of these genes
from soil bacteria might have occurred by the use of similar
genetic strategies, with ﬁnal insertion in genetic platforms
enabling efﬁcient transfer to other organisms. These plat-
forms might recruit multiple resistance genes. The wide use
of antimicrobials might determine co-selection processes that
ensure persistence of these genes in bacterial communities.
The application of metagenomic tools and phylogenetic analy-
sis will not only facilitate future identiﬁcation of other new
resistance genes and their corresponding ancestors in envi-
ronmental bacteria, but will also exploit the concept of the
resistome as a unique reservoir of antibiotic resistance genes
and genetic elements participating in resistance gene transfer.
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